Compare ARK Genomic Revolution ETF (ARKG) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs DENTSPLY SIRONA Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.61, while DENTSPLY SIRONA Inc trades at $11.46 (market cap $2.31B). The key difference: DENTSPLY SIRONA Inc pays a 5.04% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, DENTSPLY SIRONA Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | XRAY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $44.55 | $14.68 |
52-Week Low | $24.02 | $9.64 |
Market Cap | — | $2.31B |
Enterprise Value | — | $4.39B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
DENTSPLY SIRONA (XRAY) trades at $11.32, down 2.92% today, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Net income remains negative, though margins show improvement. The stock is near its consensus price target of $11.50, with support at $11 and resistance at $12.
Outlook is cautious; while cost controls and new partnerships offer potential, persistent revenue declines and high debt levels pose significant risks. Analyst sentiment is predominantly Hold, reflecting uncertainty around the turnaround plan's success amid weak dental market demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
